![Ensysce Biosciences](https://storage.googleapis.com/dealroom-images-production/90/MTAwOjEwMDpjb21wYW55QHMzLWV1LXdlc3QtMS5hbWF6b25hd3MuY29tL2RlYWxyb29tLWltYWdlcy8yMDI0LzA3LzEzLzZlOGVjM2NiODg2YzhkYzE5YzdmOTg1NjFmNWZlMWEx.png)
Ensysce Biosciences
VerifiedFocuses on developing drugs to treat pain and prevent opioid abuse.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$335k (Public information from Jul 2024)
Share price
$0.413 ENSC
San Diego California (HQ)
Deals in current and previous year:
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | - | - | - | (1209 %) | - | (7 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | - | - | (1037 %) | - | 49 % |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | $0.0 | round |
N/A | $0.0 | round | |
N/A | $0.0 | round | |
N/A | $0.0 | round | |
N/A | $0.0 | round | |
N/A | $0.0 | round | |
* | $15.0m | Grant | |
Total Funding | 000k |
Related Content
Recent News about Ensysce Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Ensysce Biosciences
Edit![Signature Therapeutics, Inc.](https://storage.googleapis.com/dealroom-images-production/f2/NzQ6NzQ6Y29tcGFueUBzMy1ldS13ZXN0LTEuYW1hem9uYXdzLmNvbS9kZWFscm9vbS1pbWFnZXMvMjAxOC8xMi8xNy9lMDg0ZDUzY2M2OGU2MTE3MWIzMGRjYjg5NjU5ZDUxMg==.jpg)
ACQUISITION by Ensysce Biosciences Jan 2016